Advanced Enzyme Technologies reported consolidated revenue of INR 2,145 million for the second quarter of FY27, a 16% increase from a year earlier and 12% above the previous quarter. The company said growth came across its business segments, while EBITDA and profit also increased. Its shares fell 2.56% to $274.25 after the results.
EBITDA rose 20% year over year to INR 721 million, lifting the margin to 34%, compared with 33% in Q2 FY26 and 28% in Q1 FY27. Profit after tax increased 14% year over year to INR 512 million. For the first half of FY27, revenue grew 10% to INR 4,062 million, while EBITDA rose 7% to INR 1,250 million and profit after tax increased 5% to INR 897 million.
Human healthcare revenue was INR 1,285 million, up 6% year over year, with the company citing improved sales in pharma APIs, bio-catalysis and nutrition. Animal healthcare revenue grew 37% to INR 265 million. Bio-processing increased 43% to INR 365 million, while specialized manufacturing rose 25% to INR 231 million.
Management said higher power, fuel and raw material costs persisted during the quarter, but operational efficiencies helped support margins. The company also noted that its completed share buyback involved 2.41 million shares acquired at an average price of INR 289.09.
Executives described the U.S. market as subdued over recent quarters but said they were seeing early signs of improvement. They indicated that a broader turnaround could take one to two quarters. Management also said some revenue had been deferred into future periods, adding to uncertainty around quarterly performance.
The company expects longer-term growth in the lower-middle double digits, or roughly 10% to 15%, and reiterated an FY27 EBITDA margin target of 30% to 32%. Planned capital expenditure for FY27 is INR 123 crore, including research and development and maintenance spending; the company said INR 50 crore to INR 60 crore had been spent in the first half.
Sources: Investing.com News.